Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-18T19:05:07.447Z Has data issue: false hasContentIssue false

Nalmefene against alcohol use disorder: A report of one case

Published online by Cambridge University Press:  23 March 2020

M. Juncal Ruiz
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
O. Porta Olivares
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
L. Sánchez Blanco
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
R. Landera Rodríguez
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
M. Gómez Revuelta
Affiliation:
Hospital Universitario de Álava-Sede Santiago, Psychiatry, Vitoria-Gasteiz, Spain
G. Pardo de Santayana Jenaro
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
R. Martín Gutiérrez
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
E. López García
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
R. Medina Blanco
Affiliation:
Hospital Universitario Marqués de Valdecilla, Psychiatry, Santander, Spain
L. García Ayala
Affiliation:
Hospital Universitario de Álava-Sede Santiago, Psychiatry, Vitoria-Gasteiz, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Alcohol consumption represents a significant factor for mortality in the world: 6.3% in men and 1.1% in women. Alcohol use disorder is also very common: 5.4% in men and 1.5% in women. Despite its high frequency and the seriousness of this disorder, only 8% of all alcohol-dependents are ever treated. One potentially interesting treatment option is oriented toward reducing alcohol intake.

Aims

To describe one case who has improved his alcohol consumption after starting treatment with nalmefene, an opioid receptor antagonist related to naltrexone.

Methods

A 35-year-old male with alcohol use disorder since 2001 came to our consult in November 2015. He was in trouble with his family and he had a liver failure. We offer a new treatment option with nalmefene 18 mg to reduce alcohol consumption.

Results

Before to start nalmefene he drank 21 drinks/week. Six-month later, he decreased alcohol intake until 5 drinks/week with better family relationship and liver function. After starting nalmefene he complained of nausea, so we recommend to take the middle of the pill for next 7 days. After this time he returned to take one pill with good tolerance and no more side effects or withdrawal syndrome.

Conclusions

Nalmefene appears to be effective and safe in reducing heavy drinking and in preventing alcohol withdrawal syndrome due to its opioid receptor antagonism. This case suggests nalmefene is a potential option to help patients, who do not want or cannot get the abstinence, in reducing their alcohol consumption.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Substance related and addictive disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.